AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
Betsy Goodfellow | April 5, 2024 | News story | Research and Development | AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT) compared to placebo after cCRT.
The drug’s safety profile remained consistent with previous trials and no new safety signals were observed.
It is anticipated that the data will be presented at an upcoming medical meeting, as well as being shared with the relevant medical authorities.
Imfinzi is already approved in the US, EU, Japan, China and various other countries, for the treatment of extensive-stage SCLC (ES-SCLC) based on results from the CASPIAN phase 3 trial. It is also the only approved immunotherapy and standard-of-care treatment for unresectable, stage 3 non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after CRT based on the PACIFIC phase 3 trial.
Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, commented: “These exciting results build on the transformative efficacy of Imfinzi in ES-SCLC and demonstrate the potential to bring a curative-intent immunotherapy treatment to this earlier-stage setting of SCLC for the first time. This data, together with the PACIFIC data in unresectable, stage 3 NSCLC, underscore the pioneering role of Imfinzi in the treatment of early lung cancer following chemoradiotherapy.”
Betsy Goodfellow
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
